GLNP Pharma

GLNP Pharma is a South Korean biotechnology company specializing in advanced drug delivery systems, specifically focusing on its proprietary Gold Lipid Nanoparticle (GLNP) platform. The company's technology aims to overcome the limitations of traditional lipid nanoparticles by enhancing stability and targeting efficiency for nucleic acid therapeutics, including mRNA and siRNA. GLNP Pharma is currently developing a pipeline of metabolic and infectious disease treatments, with a lead program focused on an oral or long-acting injectable GLP-1 receptor agonist for obesity and diabetes. By leveraging its unique nanoparticle architecture, the company seeks to provide safer and more effective delivery solutions for next-generation genetic medicines.